Efficacy of selective В1-blocker nebivolol and cytoprotector mildronate in the treatment of patients having ischemic heart disease associated with the 2nd type diabetes mellitus

The aim of the study was to assess influence of 3-months treatment using selective в1-blocker with additional NO-modulating peculiarities nebivolol, cytoprotector mildronate and their combination on clinical course, intracardiac hemodynamics and quality of life of coronary artery disease patients having chronic heart failure of the II-III functional NYHA class associated with the 2-nd type diabetes mellitus. Improved left ventricular diastolic function was revealed in all patients. The results obtained ground the expediency of including these drugs and their combination in the treatment of patients having ischemic heart disease associated the 2-nd type diabetes mellitus.